TSST

PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

Retrieved on: 
Tuesday, November 14, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, CNS, Allopregnanolone, Schizophrenia, Daphne, Trier social stress test, PureTech Health, Anxiety, Neurosteroid, Patient, Multimedia, LSE, KarXT, Alprazolam, PRTC, Psychiatry, FRCPC, Epilepsy, Pharmacology, Therapy, Benzodiazepine, Stress-related disorders, DSM-IV codes, MPH, University, TSST, Massachusetts General Hospital, Public health, Glyph, Central nervous system, Volunteering, Hospital, Pharmaceutical industry, MD

The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.

Key Points: 
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • View the full release here: https://www.businesswire.com/news/home/20231113556006/en/
    PureTech announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone).
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • An increase in cortisol levels after the TSST is a physiological response and an objective biomarker of acute stress.

ANANDA Scientific Announces First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)

Retrieved on: 
Tuesday, March 28, 2023
Research, Mental Health, FDA, Cannabis, Clinical Trials, Biotechnology, Pharmaceutical, Health, Natural Resources, Science, National Center for Complementary and Integrative Health, Alternative medicine, NCCIH, NYU, Clinical trial, Neuroimaging, New York University Grossman School of Medicine, SAD, Multimedia, Doctor of Philosophy, Prolonged exposure therapy, Assistant, TSST, Trier social stress test, Master of Science, Psychiatry, Social anxiety disorder, IND, NIH, Cannabidiol, Pharmaceutical industry, Anxiety, MD, CBD

ANANDA Scientific Inc. , a research focused bio-pharmaceutical company today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).

Key Points: 
  • ANANDA Scientific Inc. , a research focused bio-pharmaceutical company today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).
  • The National Center for Complimentary and Integrative Health (NCCIH-a division of the NIH) is providing funding for this trial which is being conducted at the NYU Grossman School of Medicine .
  • ( Clinical Trials.gov Identifier: NCT05571592 )
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230328005224/en/
    Pictured above are Principal Investigators Naomi Simon MD, MSc, Esther Blessing MD, PhD, and Ananda Scientific CEO Sohail Zaidi.

ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)

Retrieved on: 
Wednesday, November 30, 2022
Research, FDA, Cannabis, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Natural Resources, Trier social stress test, Cannabidiol, US Food Sovereignty Alliance, Principal investigator, Doctor of Philosophy, Alternative medicine, Food, Multimedia, IND, New York University Grossman School of Medicine, Master of Science, National Center for Health Research, Prolonged exposure therapy, Cannabinoid, NYU, Neuroimaging, TSST, UCLA, Psychiatry, Assistant, NIH, Social anxiety disorder, Research, PTSD, LDS, Clinical trial, FDA, Pharmaceutical industry, Medical device, Anxiety, MD, CBD

ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDAs proprietary Liquid Structure delivery technology as a potential treatment for Social Anxiety Disorder.

Key Points: 
  • ANANDA Scientific Inc ., a research focused bio-pharmaceutical company today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia A1002N5S, an investigational drug using cannabidiol (CBD) in ANANDAs proprietary Liquid Structure delivery technology as a potential treatment for Social Anxiety Disorder.
  • ( Clinical Trials.gov Identifier: NCT05571592 )
    This press release features multimedia.
  • We are delighted to be moving forward with this important study to develop new evidence-based treatments for Social Anxiety Disorder, a distressing and under-addressed condition, said Dr Simon.
  • ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD , Radiculopathic Pain , Anxiety and Opioid Use Disorder ( Mt.